Programmed Cell Death Deregulation in BCR-ABL1-Negative Myeloproliferative Neoplasms by Diaconu, Carmen C. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Programmed Cell  
Death Deregulation in  
BCR-ABL1-Negative 
Myeloproliferative Neoplasms
Carmen C. Diaconu, Petruta Gurban, Cristina Mambet, 
Mihaela Chivu-Economescu, Laura G. Necula, Lilia Matei, 
Denisa Dragu, Saviana Nedeianu, Ana I. Neagu, 
Aurelia Tatic, Diana Cristodor and Coralia Bleotu
Abstract
BCR-ABL1-negative myeloproliferative neoplasms are classically represented 
by primary myelofibrosis, polycythemia vera, and essential thrombocythemia. 
These entities are stem cell-derived clonal disorders characterized by hematopoietic 
progenitor autonomy or hypersensitivity to cytokines, most of them presenting 
mutations in Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative 
leukemia virus oncogene (MPL). Deregulation of pro- and antiapoptotic genes is 
also claimed as an important mechanism involved in cell resistance to cell death and 
accumulation of myeloid cells in myeloproliferative neoplasms. Apoptosis, as one of 
the best-characterized types of programmed cell death, has a clear role in hemato-
poiesis control. However, the exact pathways affected in BCR-ABL1-negative myelo-
proliferative neoplasms have not yet been fully clarified. This chapter will explore 
the modifications affecting programmed cell death pathways involved in myeloid 
proliferation and how these alterations might be exploited in single or combined 
targeted therapeutic strategies.
Keywords: apoptosis, programmed cell death, cancer stem cells,  
hematological disorders, cell death mechanisms, molecular interactions,  
cytokine signaling, cell-cycle inhibitors
1. Introduction
Hematopoiesis is a highly controlled process that ensures the differentiation of 
the hematopoietic stem cells (HSCs) into lymphoid and myeloid common progeni-
tors and further into all lineages of blood cells [1].
Programmed cell death (PCD) is one of the fundamental mechanisms of an 
organism’s life cycle that controls every system, including hematopoietic system, 
based on a precisely tuned signaling network. Apoptosis, the most important 
type of PCD, maybe because it is the most analyzed type of death to date, is well 
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described in hematopoietic differentiation [2]. Its deregulation in pathological 
circumstances is potentially deleterious and may influence the fate of the entire 
organism. Although different other types of PCD were described, apoptosis remains 
one of the most important processes involved in differentiation and cell survival 
regulation, while mechanisms as autophagy and necroptosis look like “backup” 
mechanisms that share some “key players” and diverged from apoptosis at a certain 
point, to assure the elimination of the malfunctioning system in case of “internal” 
defect (mutations) or pathogens that inhibit the components of the apoptotic 
network [3, 4].
Primary myelofibrosis (PMF), polycythemia vera (PV), and essential throm-
bocythemia (ET) are classic BCR-ABL1-negative myeloproliferative neoplasms 
(MPNs) that are stem cell-derived clonal disorders characterized by hematopoietic 
progenitor autonomy or hypersensitivity to cytokines, driven by acquired somatic 
mutations in critical pathways, resulting in pathological expansion of the myeloid 
lineages. In their natural course, MPNs could be exacerbated and transformed into 
secondary acute myeloid leukemia (sAML) associated with treatment resistance 
and poor clinical outcome [5].
This chapter will explore the most important modifications affecting pro-
grammed cell death pathways involved in myeloid proliferation, and how these 
alterations might be exploited in single or combined targeted therapeutic strategies 
in a classic BCR-ABL1-negative MPN.
2.  Intrinsic and/or extrinsic apoptotic pathways involved in MPN 
disease entities
Overall, the hematopoietic homeostasis requires a precise balance between 
blood cell formation and maintenance of an adequate number of mature cells. 
Although apoptosis is necessary to prevent the excessive accumulation of cells, the 
hematopoietic progenitors need to be protected and preserved. A disruption of the 
homeostatic balance in the hematopoietic system is relevant for many hematologi-
cal disorders, an increased cell death being involved in the etiology of immune 
deficiencies and anemia, while an inappropriate resistance to apoptosis might lead 
to hematological malignancies [6], such as MPNs.
As a particular form of PCD, apoptosis is activated via two convergent pathways: 
the intrinsic and the extrinsic [7]. The intrinsic signaling pathway is triggered 
at mitochondrial level in response to various stimuli such as genotoxic agents or 
growth factor deprivation, and it is mainly regulated by the members of BCL-2 
protein family that contain one or more BCL2 homology (BH) domains [8]. These 
proteins are structurally and functionally classified into three groups. The first 
group includes the critical effectors of the intrinsic pathway, namely BCL-2 antago-
nist killer 1 (BAK) and BCL-2-associated X protein (BAX). The second group is 
represented by the prosurvival BCL-2 proteins (BCL-2, BCL-xL, MCL-1, BCL-W, 
and A1) that hinder BAK and BAX activation, while the third group comprises 
several structurally different proteins, known as “BH3-only” proteins (BIM, BID, 
BAD, BIK, PUMA, and NOXA), which share solely a sequence called BH3-domain 
[8, 9]. Cellular stress signals are sensed by the “BH3-only” proteins that directly 
activate BAK and BAX or neutralize the prosurvival proteins. Once activated, 
through conformational changes, BAK and BAX induce the permeabilization of 
the mitochondrial membrane with subsequent release of apoptogenic factors, such 
as cytochrome c and second mitochondrial activator of caspases/direct IAP bind-
ing protein with low pI (SMAC/DIABLO). Cytochrome c binds to the apoptotic 
protease activating factor-1 (APAF-1) and forms the apoptosome, a heptameric 
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complex that activates the initiator caspase-9, followed by activation of the effector 
caspase-3, caspase-6, and caspase-7 that trigger final events of apoptosis [10, 11].
In the extrinsic apoptotic pathway, caspase activation is elicited at the level of 
“death receptors” (DR), transmembrane proteins of the tumor necrosis factor 
(TNF) receptor superfamily typically represented by FAS (CD95), TNF receptors, 
and TNF-related, apoptosis-inducing ligand (TRAIL) receptors. Through interac-
tion with their corresponding ligands—FASL, TNF-α, and TRAIL, respectively—
DR become activated, leading to the recruitment of a death adaptor protein, such 
as FAS-associated death domain (FADD) or TNFR-1-associated death domain 
(TRADD). Death adaptors generate a death-inducing signaling complex (DISC), in 
which procaspase-8 is recruited and activated, the death signal being subsequently 
transduced to the effector caspases [2, 10].
A very early apoptosis event is the global and rapid mRNA degradation by a 
mechanism that is not yet completely characterized [12].
Various factors associated with intrinsic and extrinsic apoptotic pathways have 
been involved in the control of adult hematopoiesis under physiological as well as 
pathological conditions [2]. In this respect, BCL-2 protein family members play 
different roles across individual hematopoietic lineages during differentiation and 
maturation. At the level of HSCs and early myeloid progenitors, MCL-1 is an essen-
tial prosurvival factor, being upregulated by stem cell factor and interleukin-3 via 
JAK/STAT (Janus-activated kinase/signal transducers and activators of transcrip-
tion) and AKT signaling pathways [13, 14]. During erythropoiesis, erythropoietin 
(EPO) ensures erythroid progenitor survival, proliferation, and differentiation by 
acting on its cognate receptor (EPO-R) and inducing JAK2-STAT5 activation that 
leads to upregulation of BCL-xL [10]. The development, maturation, and survival 
of megakaryocytes (MKC) is strictly dependent on the presence of both BCL-xL 
and MCL-1 proteins that are induced by thrombopoietin (TPO) signaling and 
restrain intrinsic apoptosis, while platelet life span seems to be dictated only by 
BCL-xL levels [7, 15, 16]. Similarly, MCL-1 is essential for granulocyte progenitor 
survival and differentiation [16]. On the other hand, the receptor/ligand interac-
tions of the TNF family represent physiological mechanisms that exert a negative 
regulation in the terminal stages of the hematopoietic differentiation, controlling in 
this way the size of the expanding hematopoietic clones and maintaining heteroge-
neity in response to various demands [17].
PV is characterized by erythrocytosis accompanied by a suppressed endogenous 
EPO production. It often associates thrombocytosis and/or leukocytosis with pan-
myelosis at bone marrow examination. The pattern of driver mutations is strikingly 
dominated by JAK2 V627F that is present in more than 95% of patients, the rest 
being represented by JAK2 exon 12 mutations [18].
A study that analyzed gene expression profile of granulocytes isolated from PV 
patients showed an upregulation of protease inhibitors with affinity for proteases 
inducing apoptosis in neutrophils (e.g., cystatin F and secretory leukocyte protease 
inhibitor), as well as of several antiapoptotic and survival factors (e.g., p38 MAPK), 
compared to granulocytes obtained from healthy subjects [19]. Also, unlike the 
granulocytes of ET patients or normal controls, the granulocytes of PV patients 
were found to express an increased amount of heat shock protein 70 (HSP70), 
which counteracts apoptosis at different levels by preventing BAX translocation to 
mitochondria, inhibiting APAF-1 and procaspase-9 recruitment to apoptosome, 
and reducing caspase activation. As shown in primary cell cultures, an HSP-70 
inhibitor was able to induce apoptosis in the erythroid lineage [20].
Concerning the extrinsic apoptosis pathway, it was found that erythroblasts 
isolated from PV patients carrying JAK2 V617F mutation exhibited an increased 
resistance to death receptor-induced apoptosis being able to generate elevated red 
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blood cell counts in the presence of CD95 and TRAIL receptor stimulation. In addi-
tion, the JAK2 mutation was correlated in PV erythroblasts with an overexpression 
of c-FLIPshort, a potent cellular inhibitor of extrinsic apoptosis [21]. Also, Tognon 
et al. reported a dysregulated expression of genes related to extrinsic apoptosis 
(FAS, FASL, FAIM, C-FLIP, TRAILRl/DR4, and TRAILR2/DR5) in bone marrow 
CD34+ cells and peripheral blood leukocytes obtained from patients with different 
MPN phenotypes, including PV [22].
ET is defined by thrombocytosis associated with normocellular bone marrow 
and hyperplasia of enlarged MKC. The molecular profile of ET consists of JAK2 
V617F mutation (in 60–65% of patients), CALR exon 9 indels (in 20–25% of 
patients), MPL exon 10 mutations (in about 4–5% of patients), and very rare non-
canonical MPL mutations (in less than 1% of patients). About 10% of ET patients 
lack these mutations being considered triple-negative cases [18].
Before the discovery of JAK2 V617F, in order to gain insight into the molecular 
mechanisms of ET megakaryopoiesis, Tenedini et al. have employed microarray 
technology to study the gene expression profiles of bone marrow CD34-derived 
MKC from ET and healthy individuals. They found in ET a downregulation of the 
proapoptotic genes BAX, BNIP3, and BNIP3L, as well as of the genes encoding for 
components of the mitochondrial permeability transition pore complex, along with 
the upregulation of the antiapoptotic and survival genes IGF1R, CFLAR (C-FLIP), 
and SDF1. Also, ET MKC exhibited in cell cultures an increased resistance to apop-
tosis, relative to their normal counterparts [23].
In a study that aimed to characterize the immunophenotypic apoptotic profiles 
of MKC on bone marrow biopsy samples obtained from MPN patients, it was 
observed that ET MKC displayed an antiapoptotic pattern, characterized by an 
overexpression of BCL-xL and a lower expression of BAX, compared to those of 
PMF patients [24]. Furthermore, Treliński et al. confirmed by flow cytometry the 
antiapoptotic profile of ET MKC and bone marrow mononuclear cells (BMMC). 
As opposed to controls, previously untreated ET patients presented significantly 
lower percentages of apoptotic MKC and BMMCs, when assessed for the number 
of annexin-V+ and caspase-3+ positive cells. These findings were accompanied 
by markedly lower BAX levels and BAX/BCL-2 ratios, especially in JAK2 V617F-
negative cases [25].
Compared to PV and ET, PMF is a more heterogeneous disease, being character-
ized by clonal myeloproliferation, abnormal cytokine expression, early bone mar-
row fibrosis, anemia, splenomegaly, extramedullary hematopoiesis, constitutional 
symptoms, and a lower overall survival rate. On the other hand, during the natural 
course of the disease PV and ET patients might suffer a conversion into secondary 
myelofibrosis (MF) that resembles PMF [26, 27]. PMF shares with ET a similar 
profile of mutations in JAK2, CALR, and MPL [18].
Initially, it was suggested that bone marrow MKC in PMF might undergo an 
increased apoptosis that could be responsible for the release of fibrogenic cytokines 
[28]. However, further studies have demonstrated that PMF MKC displayed a high 
proliferative capacity and resistance to apoptosis, explained by the overexpression 
of BCL-xL [29]. Also, the gene expression analysis of laser-microdissected MKC 
from PMF patients indicated a tendency toward an overall downregulation of 
apoptosis-associated genes, especially of BNIP3 [30].
Chronic inflammation sustained by the continuous release of proinflammatory 
cytokines and chemokines and subsequent bone marrow microenvironment altera-
tions are considered key factors in PMF pathogenesis. The abnormal production of 
cytokines that occurs both in malignant and nonmalignant cells was related to an 
increased JAK2-STAT3 activation and was found responsible for the inhibition of 
apoptosis and increased myeloproliferation, creating an environment that favors 
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MPN clone maintenance and expansion [31, 32]. Recently, it was shown that MF 
cells downregulated the expression of X-linked inhibitor of apoptosis (XIAP) and 
mitogen-activated protein kinase 8 (MAPK 8), a necessary component of TNF-
mediated apoptosis, via a TNF/TNFR2-dependent autocrine loop. This was consid-
ered a mechanism to escape an apoptotic response and to increase NF-κB signaling 
involved in inflammatory cytokine expression [33].
Overall, these data show the importance of the participation of both intrinsic 
and extrinsic apoptosis pathways in the pathogenesis of MPNs.
3. Key PCD players in BCR-ABL1-negative MPN entities
Modifications occurred in the regulation of apoptosis, especially in expression of 
pro- and antiapoptotic genes, have great contribution to the myeloaccumulation in 
MPNs. Concerning the involvement of other types of PCD in myeloproliferations, 
few data are available. Some key players are involved in apoptosis regulation and 
also in autophagy or necroptosis. More often, it is a continuous process from apop-
tosis, autophagy to necroptosis. Increased death signals and stress levels can switch 
cell death types in the attempt of eliminating the malfunctioning cells [34, 35].
BCL-2 family of proteins is a very important regulator of apoptosis and, at 
the same time, is also a negative regulator of BECN1/Beclin-1, a key regulator of 
autophagy [36, 37]. Autophagy was shown to be a major contributor to chemo-
therapy resistance in AML [38].
BCL-xL promotes cell survival, such as survival of erythroid cells and platelets, 
and regulates their lifespan at a steady state. Inhibition of BCL-xL induces profound 
thrombocytopenia by triggered BAK/BAX-mediated mitochondrial damage, cas-
pase activation, and premature death of MKC [39, 40]. In MPNs, a concerted effect 
resulted from antiapoptotic BCL-xL over-expression and proapoptotic BNIP-3 
downregulation was clearly documented [41].
Bcl-2-associated death promoter (BAD) inhibits antiapoptotic proteins BCL-2 
and BCL-xL and is involved in initiating the apoptosis process. In unphosphory-
lated form, BAD forms heterodimers with BCL-2 and BCL-xL, inhibiting their 
antiapoptotic functions, and facilitates BAX/BAK activation in response to apop-
totic stimuli [42, 43], promoting apoptosis. After activation by phosphorylation, 
BAD forms a heterodimer with 14-3-3 proteins, releasing BCL-2 that is free to block 
apoptosis. BAD is a substrate of various kinases, such as AKT, protein kinase A 
(PKA), and c-Jun NH2-terminal kinase (JNK).
Gene expression studies on CD34+ cells and peripheral leukocytes isolated from 
ET and PMF patients indicated that mRNA levels of BAX, BAD, and BIK were lower 
in JAK2 V617F-positive cases than in negative ones and, additionally, displayed a 
negative correlation with the JAK2 V617F mutational load. Also, A1, MCL1, BCLW, 
and BCL-XL genes have an increased expression in ET and PMF patients compared 
to controls. As such, Tognon et al. hypothesized that deregulated expression of 
apoptosis-related genes is linked to myeloaccumulation and pathogenesis of these 
two disorders [44].
Studies focused on the apoptosis deregulation in PV identified an increased 
expression of A1 and MCL-1 and a reduced expression of proapoptotic BAD and 
BAX genes in PV CD34+ cells compared with controls. A1 expression was also 
increased, whereas BAD and BAX mRNA levels were decreased in the leukocytes 
of PV patients versus healthy subjects [45]. Rubert et al. evaluated the roles of 
proapoptotic BIM and antiapoptotic MCL-1 in regulating JAK2 V617F-positive 
cell survival. JAK2 inhibition modified Bim-EL Ser69 phosphorylation, as well as 
decreased MCL-1 level, inducing apoptosis. On the other side, MCL-1 depletion 
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compromised cells’ viability and sensitized JAK2 V617F-positive cells to JAK2 
inhibition [46]. Also, mutant JAK2 inhibits the BCL-xL deamidation pathway and 
the apoptotic response to DNA damage in primary cells from patients PV [47]. JAK2 
V617F-positive ET patients presented markedly higher activation of caspase-3, as 
well as higher BAX expression than JAK2 V617F-negative ones [25]. Recent data 
pointed out that in ET, the MKC exhibit a more proliferative profile, while in MF, 
they display, in a larger proportion, a defective proapoptotic mechanism [24, 48].
Survivin is one of the inhibitors of apoptosis proteins (IAPs) that regulate cell 
death through mitochondrial route by restricting the IAP-inhibitor DIABLO protein 
and preventing it from activating caspase-9. A greater proportion of myeloprolifera-
tive MKC express survivin compared to its reciprocal inhibitor, DIABLO. Survivin 
seems to be the key mediator of the MKC survival signature in the MPNs and might 
be a potential therapeutic target [41]. Recently, new evidence suggested that survivin 
may be involved in the evasion of cell death by manipulation of autophagy [49].
BNIP-3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3), a pro-
apoptotic mitochondrial protein belonging to the BCL-2 family, is activated under 
hypoxic conditions with hypoxia-inducible factor (HIF-1α) in normal and cancer 
tissues. BNIP-3 is involved in the induction of hypoxic necrosis in tumors because 
it activates caspase-independent necrosis-like cell death by opening the mito-
chondrial permeability transition pore. In MPNs, BNIP-3 expression is reportedly 
low and this might indicate that the increased bone marrow cellularity is not only 
because of proliferative signaling but also due to decreased apoptosis [50, 51].
CALR is a multifunctional endoplasmic reticulum (ER) chaperone involved 
in the quality control of N-glycosylated proteins, calcium storage, and immune 
responses [27, 52]. In relation to apoptosis, CALR is implicated in the specific activa-
tion of caspase-8, BAX, and BAK, and also in the BCL-2 cleavage [53].
Caspase-8, a key factor in the extrinsic pathway, together with caspase-9, a 
key factor in the intrinsic pathway, is implicated in regulating MKC turnover [41]. 
CALR mutations particularly affect the MKC lineage as indicated by the higher 
mean number of endogenous MKC colonies in CALR-mutant MPNs than those 
found in JAK2 V617F-positive and triple-negative cases [54]. Immunohistochemical 
studies proved that CALR-mutated MKC displayed a dysregulated apoptosis 
with significant reductions in proapoptotic BNIP-3 that could explain the higher 
platelet number observed in CALR-positive MPNs, in contrast to other molecular 
subtypes [48]. Caspase-8 just like caspase-9 regulates MKC turnover in the MPNs. 
Overexpression of caspase-8 induces TP53 gene transcription to produce p53, which 
stimulates apoptotic cascade [41]. Caspase-8 uses proteolytic and nonproteolytic 
functions to change cell behavior. Activated caspase-8 triggers caspase-3 activation 
that commits cell to death [55]. (How does this relate to MPN? Is it upregulated or 
downregulated?).
Immunohistochemistry studies showed that the percentage of MKC positive for 
caspase-8 is higher in MPNs in comparison with controls, suggesting that MKC in 
MPN tend to counteract the survival advantages acquired through inhibition of the 
intrinsic apoptotic pathway by activating the caspase-8-mediated extrinsic apop-
totic cascade[41].
Caspase-9 is an inducible proapoptotic molecule, which acts relatively late in 
apoptosis signaling becoming less susceptible to inhibition by apoptosis inhibi-
tors [56]. Caspase-9 is an apoptotic initiator caspase in MKC and platelets being 
necessary for their efficient death, and it is not required for platelet generation and 
function, as it was previously thought. Thus, caspase-9 loss is associated with an 
increased MKC proliferative capacity. In MPNs, especially in the CALR-mutated 
molecular subtype, caspase-9 dysfunction could play a role in the enhanced throm-
bocytosis [40, 41].
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SMAC/DIABLO controls apoptosis by negatively regulating IAPs and by acti-
vating caspases. Recently, it was shown that silencing of SMAC/DIABLO caused 
decreased levels of phospholipids, suggesting that besides proapoptotic functions, 
SMAC/DIABLO have nonapoptotic lipid synthesis-related function essential for 
cancer growth and development. Therefore, it was assumed that SMAC/DIABLO 
could be a promising therapeutic target in cancer [57]. On the other hand, SMAC/
DIABLO downregulation was found to be associated with progressive disease and 
poor survival rate in hematologic malignancies, and DIABLO/SMAC mimetics were 
proposed as a potential adjunct therapy to enhance DIABLO levels in MPN MKC 
[41]. More studies are necessary to establish the proper therapeutic options in the 
light of the new role of SMAC/DIABLO in the phospholipid synthesis.
The tumor suppressor gene TP53 plays many roles in apoptotic landscape by 
suppressing or activating a large number of checkpoint and apoptotic genes [58]. 
Alterations in TP53 have not been linked to MKC hyperplasia although mutations 
targeting TP53 do occur during leukemic transformation of MPNs. Mutated p53 
could inhibit the wild-type p53 function or gain new oncogenic functions through 
protein-protein interactions [59]. As a result, poor prognosis in hematologic 
malignancies is correlated with mutations in TP53 due to mutant’s stability [58]. 
Elevated levels of MKC p53-positive are present more in PMF than in PV and ET 
[41]. According to Malherbe et al., CALR-mutated cases compared to JAK2 V617F-
positive cases present more p53, but not caspase-8 positivity. It seems that CALR 
lesions disrupt alternative apoptotic effectors and affected MKC attempt, a remedial 
prodeath response dominated by overexpression of p53. Also, CALR-mutated MKC 
display a minor caspase-9 upregulation that is unlikely to induce apoptosis due to 
concurrent survivin overexpression, but rather promote thrombocytosis [41].
Cell surface death receptor-ligand interaction, such as FASL binding FAS, 
TRAIL binding death receptor 5 (DR5) or TNFα binding TNFR1, executes extrinsic 
pathway apoptosis.
The two major necroptotic death effector complexes, the necrosome and 
ripoptosome, are induced by TNFR1 and toll like receptor 3 (TLR3) signaling, 
respectively [60]. IFN-R activation, primarily by type-I IFN, is believed to involve 
a caspase- and FADD-independent, receptor-interacting protein kinase (RIP) 
3-dependent mode of cell death via the formation of the necrosome. Following 
IFN-R activation, JAK/STAT signaling and the activity of RNA-responsive protein 
kinase (PKR), upstream of RIP1/RIP3 necrosome formation is essential. TNFα 
binding to TNFR1 causes recruitment of TRADD and RIP1 via their death domains 
resulting in the prosurvival complex I, which is stabilized by TNFα-bound TNFR2-
TRAF2. Internalization of the TNFR1-TRADD-RIP1 complex is required for recruit-
ment of caspase-8 and FADD, necessary for apoptosis. This is therefore a major 
cell death checkpoint as the absence of NF-κB activation and prosurvival signaling 
results in proapoptotic complexes or, alternatively, the pronecroptotic complex 
known as the necrosome. The ripoptosome consists of FADD, cFLIP and caspase-8 
and allows necroptosis to prevail if active cleavage of RIP1 by caspase-8 is prevented 
by cFLIPL. In MPN, it was shown that blocking TNFR2 but not TNFR1 selectively 
inhibits MPN cells over normal ones and the process involves XIAP, cIAP, and 
MAPK8 as key mediators of these differential responses to TNF. These data support 
the potential therapeutic use of cIAP inhibitors and selective TNFR2 inhibitors in 
the treatment of MF [33].
The TLR3-induced pathway converges with the TNFR1-induced pathway at the 
necrosome. The execution phase of necroptosis starts with interaction between 
RIP1 and RIP3. Following stabilization of the RIP1-RIP3 complex, mixed-lineage 
kinase domain-like protein (MLKL) is recruited to form a functional necrosome. 
MLKL activated upon phosphorylation by RIP3 results in the translocation of the 
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MLKL necrosome to the plasma membrane, necroptotic membrane disruption, and 
release of liposomes containing phosphatidylinositol phosphates (PIPs). This per-
meabilization, combined with MLKL-mediated calcium or sodium influx ion-pore 
dysregulation, characterizes the model proposed for necroptosis execution [60]. 
Human cancers, including MPN and their exacerbated form, sAML, are known for 
eluding apoptosis; therefore, therapeutic induction of necroptosis may represent a 
better strategy for an efficient treatment. A series of compounds have been shown 
to trigger necroptosis, particularly inhibitors of RIP1, RIP3 or MLKL, in leukemia 
cells; however, a deeper understanding of the signaling network that regulates this 
type of PCD is still necessary [35].
4.  Major signaling pathways involved in apoptotic failure in molecular 
subgroups of MPN
The constitutive activation of JAK-STAT pathway is a common feature of 
MPNs irrespective of driving mutation, being observed even in so-called “triple-
negative MPNs” that lack known JAK2, MPL, and CALR mutations [41, 48, 61]. 
In contrast to the transient activation of the JAK-STAT signaling that occurs in the 
physiological conditions, MPNs are characterized by a hyperactive JAK2 signaling 
through dimeric myeloid cytokine receptors (EPO-R, TPO-R, and G-CSFR) even 
in the absence of the ligand that promotes myeloproliferation and resistance to 
apoptosis (Figure 1) via the JAK-STAT, PI3K (phosphatidylinositol 3-kinase)-AKT 
signaling pathways, and ERK/MAPK pathways [62, 63]. While the most prevalent 
MPN driver mutation, JAK2 V617F, induces the activation of all three myeloid 
cytokine receptors, MPL and CALR mutations activate only TPO-R. This provides 
Figure 1. 
Major signaling pathways involved in apoptotic failure in molecular subgroups of MPN.
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an explanation for the association of JAK2 V627F mutation with all classical MPN 
phenotypes (PV, ET, and PMF) and also for the preferential occurrence of MPL and 
CALR mutations in ET and PMF.
In addition, loss-of-function or neomorph mutations in genes that are involved 
in epigenetic regulation, splicing, and signaling can act as disease modifiers by 
cooperating with MPN driver mutations [52].
The JAK/STAT is the major pathway (Figure 1a) involved in MPN pathology 
[64–66]. JAK2 V617F mutation promotes constitutive activation of JAK-STAT 
signaling, erythrocytosis and MKC proliferation, extensive cellular hyperplasia, 
and abrogated apoptosis [67, 68]. In response to JAK2 V617F mutation, extensive 
proliferation conduces to accumulation of irreparable DNA damage. As a con-
sequence, internal apoptotic cascade is triggered with higher BNIP-3 positivity 
that stimulates MKC apoptosis [69, 70]. This is counteracted by the antiapoptotic 
effects conferred by excess BCL-XL expression induced by phosphorylated STAT5 
(pSTAT5) and pSTAT3. BCL-xL expression is essential to maintain megakaryoblast 
lineage survival and platelet production, preventing lethal hemorrhage [15].
The MAPK/ERK signaling pathway activation (Figure 1b) is required in MKC 
differentiation, with TPO as signal for induced maturation via MPL receptor 
[71]. JAK2 V617F can activate MAPK signaling pathway via receptor tyrosine 
kinase-Grb2-SOS, continuing with RAS GTPase and RAF-1, which activates MEK, 
followed by ERK activation [72]. Phosphorylated extracellular signal-regulated 
kinase (ERK) activates BCL-2 and BAD, both of which have the effect of inhibiting 
apoptosis.
An increased activation of RAS/RAF/ERK pathway was showed in MPN 
patients, especially in erythroid precursor cells and MKC (Figure 1b). It was 
shown that ERK is constitutively activated by the JAK2 V617F mutation. Laubach 
JP et al. demonstrated an increased activation of RAS/ERK pathway in PV, associ-
ated with a dysregulated erythropoiesis and apoptosis resistance of erythroid 
precursor cells [73]. ET, PV, and PMF patients with JAK2 V617F mutation demon-
strated an increase of ERK phosphorylation level in MKC. Phosphorylated ERK 
activates BAD, which release apoptosis inhibitor BCL-2, resulting in an overall 
inhibition of apoptosis that may be the cause of MKC hyperplasia and bone mar-
row hypercellularity [50].
The PI3K/AKT signaling pathway (Figure 1c) may be activated by the JAK2 
V617F mutation or pSTAT5. PI3K/AKT pathway is involved in several cellular 
processes including cell proliferation and differentiation, protein synthesis, 
and apoptosis. AKT pathway is known to be active in AML [74, 75]. Dai C et al. 
showed that increased erythroid progenitor proliferation from PV is associated 
with increased phosphorylation of AKT [76]. Khan I et al. confirmed that PI3K/
AKT signaling pathway was activated in MPN by the JAK2 V617F and MPL W515 L 
mutations [77]. Moreover, Koopmans et al. demonstrated an increase of pAKT 
level in the cytoplasm and nucleus of immature myeloid cells and in MKC of MPN 
patients. Immunohistochemical staining showed that pAKT expression was signifi-
cantly higher in MKC of ET compared to PV and PMF. Recently, the AKT activation 
was demonstrated to be a feature of CALR-mutant myeloproliferative neoplasms 
[78]. The higher platelet counts reported in MPN with CALR mutations may be due 
to greater dysregulation of MKC apoptosis [48]. Consequently, AKT was considered 
a potential target in MPN therapy. Several studies have shown that targeting AKT 
with specific inhibitors reduced cell growth in vitro [77] and induced prolonged 
survival of the immunodeficient mice injected with JAK2 V617F-mutated cells, 
along with reducing spleen size [79].
The activation of AKT upregulates BCL-xL and inactivates BAD, suppressing 
apoptosis and promoting cell survival. This was observed in MPN patients, where 
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the activation of pAKT was higher in MKC and associated with the inhibition 
of MKC apoptosis [50]. pAKT is also known to induce activation of BNIP-3 and 
caspase-9 through mammalian target of rapamycin (mTOR)—a serine/threonine 
kinase that is an effector protein of AKT—via activation of HIF-1. Data related 
to BNIP-3 expression are conflicting; some groups reported a reduced BNIP-3 
expression [30], whereas others have shown its upregulation in MPNs [50]. In the 
study of Koopmans et al., the immunohistochemical expression of BNIP-3, with 
proapoptotic function, was lower in total bone marrow cells of ET, PV, and PMF 
patients, compared with the control group. This suggests that a decreased apoptosis 
might also contribute to the increased bone marrow cellularity observed in MPNs. 
However, in contrast to total bone marrow cells, the MKC of MPN patients were 
found to display a high level of BNIP-3 [50]. On the other hand, the most pro-
nounced reductions in BNIP-3 were observed in PMF, suggesting a loss of proapop-
totic potential during progression to the “accelerated” phase of MPNs [80].
JAK2 exon 12 mutations, exclusively associated with PV, consist of deletions/
insertions, duplications, and point mutations, which affect a conserved region in 
the proximity of JAK2 pseudokinase domain (residues F537 through E543) and have 
functional consequences similar to those induced by JAK2 V617F, however with 
some quantitative and qualitative differences [81]. Thus, exon 12 mutations cause a 
constitutive activation of EPO-R (Figure 1a) with erythroid hyperplasia, and lesser 
involvement of other hematopoietic lineages [82, 83]. Unlike JAK2 V6217F, that is 
commonly homozygote in PV, at least in a proportion of colonies, exon 12 mutations 
are predominantly heterozygous, suggesting a stronger activation of JAK2 signaling 
[82, 84, 85]. As indicated by the levels of pAKT in the erythroid colonies, JAK2 exon 
12 mutations are associated with a weaker activation of AKT signaling compared to 
JAK2 V617F. Both JAK2 V617F and JAK2 exon 12 mutations block the DNA damage-
mediated apoptosis through inhibition of the BCL-xL deamidation pathway [81].
MPL exon 10 mutations induce an increased TPO-R signaling (Figure 1d) 
resulting in the activation of STAT5, STAT3, ERK, and AKT with associated throm-
bocytosis [86]. The most prevalent MPL mutations include substitutions of the jux-
tamembrane tryptophan W515, mainly by leucine (W515 L) or lysine (W515K) and 
rarely by alanine (W515A) or arginine (W515R). As tryptophan W515 is part of the 
amphipathic helical motif RWQFP that prevents TPO-R self-activation, these sub-
stitutions cause a cytokine-independent activation of the receptor [87, 88]. In this 
respect, in vitro expression studies of MPL mutants indicated that MPL W515K/L 
mutations were able to induce spontaneous cell proliferation and activation of JAK/
STAT, RAS/MAPK, and PI3K/AKT pathways. In addition, an antiapoptotic effect 
was observed after cytokine withdrawal in MPL W515K/L-expressing cell lines, 
characterized by high levels of BCL-xL expression [89]. A second type of exon 10 
MPL driver mutations, S505 N [52], was initially described as a germline mutation 
in a Japanese family suffering from hereditary thrombocytosis. Functional studies 
revealed that cell lines expressing S505 N presented growth factor-independent 
survival capacity accompanied by a constitutive phosphorylation of MEK1/2 and 
STAT5b. Furthermore, an autonomous phosphorylation of MEK1/2 was also noticed 
in the platelets obtained from the affected family members [90]. Later on, the same 
MPL mutation was reported as somatic in less than 1% ET cases [91].
Noncanonical MPL mutations (outside exon 10) of somatic or germline origin 
have been identified by whole-exome sequencing (WES) in approximately 10% of 
triple-negative ET or PMF cases [92]. By performing several functional assays, it 
was shown that all MPL mutations were gain-of-function resulting in activation of 
JAK2-STAT5 signaling. In a different study, the MPL somatic mutation S204P could 
induce TPO-independent growth, resistant to cytokine deprivation and constitutive 
STAT activation, although less efficient than MPL W515K mutation [93].
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CALR mutations are located in the exon 9 of the gene and induce a + 1 base-
pair frameshift, resulting in a new C-terminus that loses the ER retention motif 
(KDEL). Although more than 50 CALR mutations have been described so far, the 
mutation profile is dominated by a 52-bp deletion (type 1 mutation) and a 5-bp 
insertion (type 2) [94]. Functionally, both type 1 and type 2 CALR mutants bind 
to the extracellular domain of TPO-R and cause its activation (Figure 1e), lead-
ing to constitutive JAK2/STAT/PI-3 K and MAPK signaling and protecting cells 
from apoptosis [95]. Recently, by using gene expression analysis of K562 cells that 
lack TPO-R and stably express either CALR WT or the two most common CALR 
mutants, Salati et al. have identified a novel potential role of CALR mutations in 
MPN development, independent of TPO-R activation. Thus, CALR mutants seemed 
to diminish the proapoptotic signals downstream the unfolded protein response, 
generating the accumulation of misfolded proteins in ER and promoting resistance 
to ER stress-induced apoptosis [96].
Taking into account the above-mentioned cellular and molecular effects of 
MPN driver mutations, we can assume that megakaryocytic and erythroid progeni-
tor expansion in MPNs results from a combination of increased proliferation and 
attenuated apoptosis.
5.  PCD resistance in myeloid proliferation exploited in single or 
combined targeted therapeutic strategies
As shown previously, deregulation of the JAK/STAT pathway is central to MPN 
development and is driven in most cases by activating mutations in JAK2, CALR, or 
MPL. Signaling through other pathways (RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, 
and LNK) and alterations in other cellular processes such as DNA methylation (e.g., 
TET2 and DNMT3A mutations), histone modification (ASXL1 and EZH2 muta-
tions), and RNA splicing (U2AF1, SF3B1, and SRSF2 mutations) further contribute 
to initiation, progression of myeloproliferation, and resistance to apoptosis [52, 97].
Understanding molecular mechanisms of MPN pathogenesis has stimulated 
drug development in the field.
Reduction of thrombotic risk is the major goal of therapy in patients with PV 
and ET, and hydroxyurea (HU) is normally the first-line drug for achieving cyto-
reduction [98, 99]. In addition, most patients should receive aspirin, if they have 
no contraindications. In PV, maintaining hematocrit values <45% is an important 
therapeutic target. Second-line drugs of choice are interferon-α (IFNα) and busul-
fan [99].
The clinical efficacy of IFNα has been reported since 30 years ago and was 
improved with the development of pegylated forms [100, 101]. Furthermore, sig-
nificant reductions of the JAK2 V617F allele burden (% JAK2 V617F) was observed 
in IFNα-treated patients [102, 103], suggesting that IFNα is able to target the 
malignant clone. The mechanism of action of IFNα in MPNs is not clearly eluci-
dated, but several studies confirmed a targeted effect against JAK2 V617F mutant 
clones. Ropeginterferon alpha-2b (Ropeg) is a long-acting pegylated-IFNα-2b, 
recently shown to be safe and well tolerated in phase 1–2 studies in PV patients. 
Both hematological and molecular responses have been reported in a phase 2 trial 
[104]. The discovery of JAK2 V617F mutation and its role in constitutive activation 
of downstream signaling pathways and MPN pathogenesis triggered the search for 
specific JAK2 kinase inhibitors as potential targeted therapy. One of the first mol-
ecules approved for targeted treatment of MPN patients, ruxolitinib/jakafi (RUX), 
a selective JAK2 and JAK1 inhibitor, is currently used in PV resistant or intolerant to 
HU, and in intermediate and high risk PMF [99, 105]. RUX, approved in 2014 based 
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on the results of the RESPONSE trial [106, 107], inhibits ATP-binding catalytic site 
of JAK kinase domain (both in mutant and wild type JAK), thus leading to a reduc-
tion of phosphorylation level of STAT-3/5, ERK, and AKT [108, 109]. Initial studies 
showed that RUX treatment of JAK2 V617F-positive Ba/F3 cells inhibited cell 
proliferation and induced apoptosis [108]. The drug was able to cause apoptosis by 
decreasing BCL-xL, as well as proviral integrations of Moloney virus (PIM) 1 and 2 
at transcriptional level, and consequently by inhibiting BAD phosphorylation [110].
RUX showed efficiency in spleen size reduction and symptomatology allevia-
tion, improving quality of life, and overall survival; however, no significant 
decrease in allele burden was achieved [11, 111, 112]. RUX effects on the malignant 
clone are modest, side effects (such as anemia and thrombocytopenia) are reported, 
and drug resistance may appear. Other therapeutic strategies have been developed; 
they include the discovery of new inhibitors that target specifically mutant JAK2 
and the combination of current therapies with other molecules that inhibit compo-
nents of signaling pathway [105].
Early studies provided some evidence for the increased resistance to apoptosis 
of PV erythroid progenitor cells: overexpression of BCL-xL in the absence of EPO 
and a higher sensitivity to the antiapoptotic growth factor IGF-1 [113]. Moreover, 
Zeuner et al. have shown that erythroid precursors in PV patients with average and 
high JAK2 V627F mutational load often expressed elevated levels of BCL-2 and 
BCL-xL and were very susceptible to the apoptosis induced by the BH3 mimetic 
ABT-737 (a small-molecule that inhibits BCL-2, BCL-xL, and BCL-W and causes 
apoptosis of the leukemic cells) compared to JAK2 V617F-low or normal erythro-
blasts [114]. Later, the combination of ABT-737 with a JAK inhibitor proved to be 
efficient in reducing the number of PV JAK2 V617F+EPO-dependent and inde-
pendent erythroid colonies, and BIM was identified as a key mediator of apoptosis 
induced by JAK2 inhibition [115].
In susceptible cells, apoptosis is caused by exposure to a JAK inhibitor, which 
leads to dephosphorylation of BAD, enabling BAD to bind and sequester the anti-
apoptotic protein BCL-xL. On the other side, in potent cells, RAS effector pathways 
keep BAD phosphorylation in the presence of JAK inhibitors, maintaining a specific 
dependence on BCL-xL for survival. So, downstream regulation of BCL-xL, more 
precisely BCL-xL inhibition, might be the key against resistance to JAK inhibition 
by either co-inhibition of JAK and RAS effector in AKT and ERK pathways or by 
direct inhibition of BCL-xL inducing apoptosis [116].
At present, there are over 1500 clinical trials evaluating various drug effects on 
myeloproliferative neoplasms registered at clinicaltrials.gov. Some of them might be 
successful due to targeting different apoptotic pathways or by targeting simultane-
ously different types of PCD.
Plitidepsin is a synthetically produced anticancer agent [117], a cyclodepsipep-
tide related to didemnins, commercialized as Aplidin® (PharmaMar, S.A., Madrid, 
Spain). Plitidepsin induces dose-dependent cell-cycle arrest and an acute apoptotic 
process. These effects rely on the induction of early oxidative stress, the rapid acti-
vation of Rac1 GTPase, and the sustained activation of JNK and p38/MAPK, which 
finally result in caspase-dependent apoptosis [118, 119]. JNK phosphorylation can 
be seen as early as 5–10 minutes after exposure to the compound. The activation 
of JNK and p38/MAPK is associated with increase in reactive oxygen species and a 
decrease in reduced form of glutathione [120].
Recent studies have led researchers to hypothesize that the primary target 
of plitidepsin could be the eukaryotic elongation factor 1A2 (eEF1A2), which is 
overexpressed in tumors and supports tumor cell proliferation while inhibiting 
apoptosis [121]. eEF1A2 seems to be an interesting target for therapy and may also 
be a biomarker predicting drug sensitivity. Aplidin®/Plitidepsin was investigated for 
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its effect (safety and tolerability) on bone marrow or peripheral blood cells as well as 
assessed the response rate in patients with PMF, post-PV MF, or post-ET MF, in phase 
II/open label single agent clinical trial (NCT01149681). Although the drug was well 
tolerated, the trial was prematurely terminated due to the low response rate [122].
Navitoclax is an orally active, synthetic small molecule and an antagonist of the 
apoptosis suppressor proteins BCL-2, BCL-xL, and BCL-w, which are frequently 
overexpressed in a wide variety of cancers, including myeloid ones, and are linked 
to drug resistance. Inhibition of these apoptosis suppressors prevents their binding 
to the apoptotic effectors BAX and BAK proteins, thereby triggering apoptotic pro-
cesses in cells overexpressing BCL-2, BCL-xL, and BCL-w. This eventually reduces 
tumor cell proliferation. Navitoclax (ABT-263) and RUX are currently evaluated in 
combination for efficacy, safety, and tolerability on spleen volume as assessed by 
magnetic resonance imaging (MRI) in participants with MF in a phase II/open label 
clinical trial (NCT03222609).
Obatoclax (GX15–070) is a BH3-mimetic designed to target and counteract anti-
apoptotic BCL-2 proteins. Obatoclax is an MCL-1 antagonist [123] and downregu-
lates p53, and it has a dual mechanism of action, being capable to induce apoptosis 
or autophagy [124]. On the other side, obatoclax accumulates in lysosomes inducing 
their alkalinization and inhibiting their function [125]. Parikh et al. conducted a 
multicenter, open-label, noncomparative phase II study (NCT00360035) of obato-
clax in patients with MF. Unfortunately, obatoclax exhibited no significant clinical 
activity at the tested dose and schedule [126].
Other phase I trial (NCT02436135) investigated the combination of RUX with 
idelalisib, a PI3K delta inhibitor, as therapy for intermediate to high-risk PMF, post-
PV MF, or post-ET MF with progressive or relapsed disease [127].
PIM inhibitors have shown preclinical synergy with JAK inhibitors, as well as the 
ability to overcome JAK inhibitor resistance in MPN cell lines. PIM regulate JAK/
STAT signaling and are involved in oncogenesis through phosphorylation of cell 
cycle regulators, activation of antiapoptotic proteins, and enhancement of MYC 
expression [97]. A phase 1b study of RUX plus PIM inhibitor PIM447, or RUX plus 
CDK4/6 inhibitor ribociclib (LEE011), or the combination of all three is underway 
in several non-U.S. countries (NCT02370706).
As PI3K/AKT/mTOR signaling is markedly activated in MPNs, small molecule 
inhibitors of the proteins involved in this pathway have been tested in MF with 
promising results. Thus, mTOR inhibitor everolimus, as single therapeutic agent, 
was able to induce responses, in terms of reducing constitutional symptoms and the 
degree of leukocytosis, thrombocytosis, and anemia, in 23% of patients in a phase I/
II clinical trial. Due to the preclinically proved synergic effects of PI3K/AKT/mTOR 
inhibitors and JAK inhibitors, several clinical studies were initiated: PI3K inhibitor 
TGR-1202 in combination with RUX (NCT02493530), PI3K inhibitor buparlisib 
with RUX (NCT01730248), PI3K inhibitor INCB050465 and RUX (NCT02718300), 
and selective PI3Kδ inhibitor TGR-1202 and RUX (NCT02493530). Preliminary 
results of buparlisib and RUX phase 1b study indicated that this drug association 
was well tolerated, and ≥ 50% reduction in splenomegaly was observed in 70% of 
JAK-inhibitor naive patients and 54% of patients who did not previously respond to 
JAK2 inhibitor monotherapy [97, 127].
RAF/MEK/ERK pathway is another signaling cascade activated in MPNs by the 
increased JAK/STAT signaling. Therefore, MEK inhibitors were tested in different 
murine models, either alone or in combination with JAK inhibitors, showing a 
decrease in bone marrow fibrosis, inhibition of malignant cell growth, and HSC 
function recovery, associated with a prolonged survival. Moreover, a new trial that 
combines the MEK inhibitor selumetinib with the DNA hypomethylating agent 
azacitidine is soon expected [97].
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Preclinical studies reveal a central role for tumor necrosis factor alfa (TNF-α) in 
promoting clonal dominance of JAK2 V617F-expressing cells in MPN [101]. JAK2 
V617F appears to confer TNF-α resistance to a preneoplastic TNF-α-sensitive cell, 
while creating a TNF-α-rich environment at the same time.
SMAC-mimetics are novel apoptosis-inducing agents that stimulate the ubiqui-
tinylation and proteasomal degradation of cellular inhibitors of apoptosis (IAPs) 
[102], proteins that play an important role in tumor cell resistance to cytotoxicity 
mediated by TNF superfamily cytokines. These agents have been shown to sensitize 
cancer cells to TNF family-induced apoptosis [103]. Results from a phase II trial of 
the SMAC-mimetic LCL-161 in patients with intermediate or high-risk MF intoler-
ant of, ineligible for, or relapsed/refractory to JAK inhibitors were recently pre-
sented. Six of sixteen evaluated patients (38%) had objective responses, obtaining 
clinical improvement and in one case cytogenetic remission [128].
Resistance of hematologic malignancies to PCD significantly limits the efficacy 
of chemotherapy. As the majority of chemotherapeutic drugs trigger apoptosis, 
the observed resistance may indicate that novel therapeutic strategies to reactivate 
nonapoptotic PCD or at least combined therapeutic strategies able to attack simul-
taneously different mechanisms might be better approaches to eradicate malignant 
cells.
6. Conclusion
Deregulation of pro- and anti-PCD genes involved in cell resistance to cell 
death and accumulation of myeloid cells in MPNs is continuously clarified by 
intense exploration of the modifications affecting different types of PCD pathways 
involved in myeloid proliferation. At the same time, comprehension of the network 
of signaling pathways involved in etiology and drug resistance of these disorders 
facilitate a more efficient exploitation of the knowledge, using combined and 
synergic, targeted therapeutic strategies.
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